Vacc 4x
Alternative Names: HIV vaccine Vacc-4x; Vacc-4x; ™Kick, Kill and Boost strategy - Bionor HoldingLatest Information Update: 03 Dec 2019
At a glance
- Originator Bionor Immuno
- Developer Bionor Holding; Bionor Pharma; Celgene Corporation; Eurocine; Oslo University Hospital; University of Bergen; University of Oslo
- Class AIDS vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II HIV-1 infections
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 06 Aug 2019 Bionor Holding completes the phase II trial in HIV-infections in Denmark (EudraCT2015-003186-28)
- 31 Jul 2019 Vacc-4x is still in phase II development for HIV-1 infections (Combination therapy) in Denmark (Intradermal) (EudraCT2015-003186-28)